Are you overlooking the “X Factor” in Biopharma M&A? asks JLL expert

12 March 2014
mergers-acquisitions-big

When Merck & Co (NYSE: MRK) acquired Schering-Plough in 2009, the corporate real estate team reduced the combined companies’ occupancy costs by $300 million within three years - making a significant contribution to the $3.5 billion merger synergy goal. For Merck, the value hidden within the corporate real estate portfolio was the “X factor” that contributed to the transaction's success.

According to professional services and investment management firm JLL experts, biotechnology and pharmaceutical companies, including small and mid-size firms, can ensure a positive M&A by using three primary strategies: engage the real estate and facilities function early; identify immediate integration cost savings; and be diligent about change management for long-term success.

“While real estate is only one of the key factors that determine the success of a merger or an acquisition, it is often the ‘X factor’ where contributions that surpass expectations can be found,” says Roger Humphrey, executive managing director of JLL’s Life Sciences team, who led Merck’s corporate real estate department during the Schering-Plough merger. “When used strategically, corporate real estate can help a buyer edge out the competition for the greatest return on the deal,” he stated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical